Stockwinners Market Radar for August 25, 2017 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

17:33 EDT Discovery Capital reports 8.9% stake in Peabody Energy

17:10 EDT Oaktree Capital reports 5.2% passive stake in Resource Capital

17:01 EDT Amedica receives Nasdaq notification over continued non-compliance - Amedica Corporation disclosed that on August 22, 2017, it received notification from the Nasdaq Listing Qualifications Staff indicating that the company's continued non-compliance with the minimum $1.00 per share bid price requirement could serve as a basis for delisting from Nasdaq as could the company's continued non-compliance with Nasdaq's filing requirement unless the company timely requests a hearing before the Nasdaq Hearings Panel. The company intends to timely request a hearing before the Panel, at which hearing it will present its plan to evidence compliance with all requirements for continued listing on The Nasdaq Capital Market. The company's request for a hearing will stay any suspension/delisting action by Nasdaq at least pending the issuance of the Panel's decision following the hearing and the expiration of any extension granted to the company by the Panel. The company said it is diligently working to evidence compliance with all applicable requirements for continued listing on The Nasdaq Capital Market; however, there can be no assurance that the Panel will grant the company's request for continued listing or that the company will regain compliance with the applicable criteria within the period of time that may be granted by the Panel.

16:48 EDT Parker Aerospace, Oxsensis enter aerospace engine agreement - Parker Aerospace, a business segment of Parker Hannifin, and Oxsensis have signed a contract to develop sophisticated aerospace engine sensor technology. Together the two companies will develop harsh-environment instrumentation including static and dynamic pressure and temperature sensors for aerospace engine applications, based on innovative fiber optic sensor technologies. These include direct-mount sensors operating up to 1,800 degrees F that are already successfully deployed in land-based gas turbine systems.

16:38 EDT Burcon NutraScience receives Nasdaq letter of non-compliance - Burcon NutraScience announced that, further to the company's news release on June 14, it received a second letter on August 21, 2017 from the Listings Qualifications Department of the Nasdaq Stock Market notifying the Company that it is not in compliance with Listing Rule 5450 (a)(1), which requires the listed securities of the Company to maintain a minimum bid price of $1 per share. The Company has not met this requirement for a period of 30 consecutive business days. The Nasdaq notification letter does not result in the immediate delisting of the Company's common shares, and the shares will continue to trade uninterrupted under the symbol "BUR." The Company has a compliance period of 180 calendar days, or until February 19, 2018, to regain compliance with Nasdaq's minimum bid price requirement. If at any time during the compliance period the Company's closing bid price is at least $1 for a minimum of 10 consecutive business days, Nasdaq will provide Burcon with a written confirmation of compliance and the matter will be closed.

16:34 EDT Plains All American: Timing of call partially due to weather concerns - Says timing of call partially due to weather concerns, "adequate" time to discuss matters. Comments taken from update call to discuss results of leverage and distribution review.

16:31 EDT Plains All American: Long-term view for crude oil sector 'strong' - Says long term view for the crude oil sector and for PAA is strong. Says U.S. Lower 48 crude oil production positioned to grow significantly over the next several years. Says Permian Basin the most attractive and significant growth region. Says well positioned to grow fee-based businesses. Says production outlook remains generally in line with expectations provided during May investor day. Comments taken from slides for update call to discuss results of leverage and distribution review.

16:16 EDT Morgan Stanley reports 5.1% passive stake in Hibbett Sports

16:09 EDT Plains All American: Timeliness, hurricane reasons for timing of Friday call - Greg Armstrong, Chairman and CEO of Plains All American, "acknowledged the inconvenience of a Friday afternoon press release and conference call, but noted that the timing was driven by a desire to timely communicate this information to the market following the board's Thursday afternoon meeting and avoid potential delays associated with Hurricane Harvey."

16:07 EDT Plains All American sees reaching targeted credit metrics within next 6 quarters - Plains All American Pipeline (PAA) Chairman and CEO Greg Armstrong, in relation to the company and Plains GP Holdings' (PAGP) planned actions related to their leverage and distribution review, said, "We believe the steps we are taking represent a solid, executable and measurable plan that will reduce debt by approximately $1.4B and enable us to reach our targeted credit metrics within the next 6 quarters. Additionally, these actions will minimize, if not eliminate common equity issuance to fund our current and future routine capital projects and position PAA for sustainable multi-year distribution growth in 2019, underpinned by healthy fee-based distribution coverage."

16:04 EDT Castle Creek Capital reports 5.4% stake in The Bancorp

15:57 EDT Plains GP Holdings trading resumes

15:52 EDT EQS Group reports 5.63% stake in Issuer Direct Corp.

14:40 EDT Monster Digital announces filing of proxy related to proposed merger - Monster Digital announced the filing with the U.S. SEC of Monster Digital's preliminary proxy statement in connection with the proposed combination of Monster Digital and Innovate Biopharmaceuticals. As previously announced, on July 3, Monster Digital and Innovate entered into a definitive agreement under which Monster Digital and Innovate will combine in a stock-for-stock transaction.

14:17 EDT Plains GP Holdings trading halted, news pending

14:08 EDT Boeing, Japan Investment Adviser finalize $1.12B 737 MAX 8 order - Boeing and Japan Investment Adviser finalized an order for Boeing 737 MAX 8 airplanes, valued at $1.12B at current list prices. The order was previously announced as a commitment at the 2017 Paris Air Show in June.

13:38 EDT Harris raises quarterly dividend 8% to 57c per share - The Board of Directors of Harris Corporation has increased the quarterly cash dividend by 8% from 53c per share to 57c per share and declared a quarterly cash dividend of 57c per share, payable September 22 to shareholders of record September 8. The annualized cash dividend correspondingly increases from $2.12 per share to $2.28 per share. The action represents the company's 16th consecutive annual dividend increase

12:00 EDT GameStop slips after earnings miss despite assurances for 'better' second half - Shares of GameStop (GME) plunged after the video game retailer reported second quarter results, with adjusted earnings for the quarter falling short of consensus estimates. The company also noted a decline in U.S. comparable store sales in the quarter as well as a dip in new software sales and pre-owned sales. WHAT'S NEW: After the market close yesterday, GameStop reported Q2 adjusted EPS of 15c on revenue of $1.69B, compared to analysts' forecasts of 16c and $1.64B, respectively. Comparable store sales grew 1.9% in Q2, with U.S. SSS falling 1.4% and international SSS growing 9.8%. New hardware sales in Q2 grew 14.8%, led by continued demand for the Nintendo Switch (NTDOY), though new software sales and pre-owned sales fell 3.4% and 7.5%, respectively, impacted by lagging Xbox One (MSFT) sales. The company also said that digital sales grew 28.1% and collectibles sales increased 36.1% in the quarter. Looking ahead, GameStop reaffirmed its fiscal 2017 EPS guidance of $3.10-$3.40 and sees FY17 SSS to be at the high end of its previously stated guidance range of (5%)-0%. Analysts expect the company to report FY17 EPS of $3.31. CEO BULLISH ON BACK HALF: On the company's earnings call, GameStop chief executive officer Paul Raines said that he sees "better" results for the retailer in the second half of the year, driven by continued Switch demand and the launch of the Xbox One X. In an interview on CNBC today, Raines said that the strength of the Nintendo Switch shows there's still a place for console gaming and added that there's "tremendous demand" for future Switch products. STREET RESEARCH: Following the quarterly report, SunTrust analyst David Magee maintained a Buy rating on GameStop and said he would "downplay" the importance of the EPS miss, noting that various categories performed "roughly as expected." The analyst added that Q2 is the retailer's weakest quarter from a seasonal perspective and that the company should have a "strong" second half. In addition, Baird analyst Colin Sebastian backed his Outperform rating and $21 price target on GameStop, saying that Q2 results were in line with his expectations, though gross margins came in a bit light. Sebastian said that the stock should benefit from seasonal category strength, and the ongoing hardware ramp from the Switch and Xbox One X, improving pre-owned and tech brand trends. Wedbush analyst Michael Pachter also kept an Outperform rating on the stock, noting that the retailer has the highest market share of Switch hardware and software in the U.S. and in most of its international markets. On the other hand, Pachter said that the technology brands business underperformed relative to his expectations yet again, and that the uncertainty over how successful the Xbox One X launch will be as well as a "tepid" debut for the PS4 Pro (SNE) could put pressure on physical software sales later this year, which have generally disappointed in recent years due to the growth of digital spending. PRICE ACTION: At midday, shares of GameStop (GME) slipped 12.7% to $19.01. OTHERS TO WATCH: Game makers Electronic Arts (EA), Activision Blizzard (ATVI), and Take-Two (TTWO) each fell a bit over 1% near noon.

11:48 EDT Box Office Battle: Cinemas looking at worst August weekend in almost 25 years - This weekend could be the worst August weekend the U.S. box office has seen in almost twenty-five years, with a top twelve that may not reach $50M combined, according to Box Office Mojo, which noted that this hasn't happened since August of 1993. One of the biggest factors expected to impact the weekend is Saturday night's Mayweather-McGregor boxing match. Lionsgate's (LGF.A, LGF.B) "The Hitman's Bodyguard," an action comedy starring Ryan Reynolds and Samuel L. Jackson that opened last weekend and finished atop the box office, is expected to remain on top this weekend with a domestic gross of about $10M. Time Warner's (TWX) Warner Bros/New Line's horror prequel "Annabelle: Creation" is expected to finish in second place with a gross of about $7.5M. The Weinstein Co.'s animated feature "Leap!," which is opening this weekend, is expected to gross $4M-$5M. Warner Bros.' war epic "Dunkirk," which is in its sixth weekend at theaters, is expected to gross an additional $4M-$5M. Other publicly traded companies in filmmaking include 21st Century Fox (FOX, FOXA), Comcast (CMCSA, CMCSK), Disney (DIS), Sony (SNE), and Viacom (VIA, VIAB).

11:29 EDT Novo Nordisk says FDA approves new indication for Victoza - The U.S. Food and Drug Administration has approved a new indication for Victoza to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established CV disease. The FDA's decision is based on the results from the landmark LEADER trial, which demonstrated that Victoza statistically significantly reduced the risk of cardiovascular death, non-fatal heart attack or non-fatal stroke by 13% vs placebo, when added to standard of care, with an absolute risk reduction of 1.9%. The overall risk reduction was derived from a statistically significant 22% reduction in cardiovascular death with Victoza treatment vs placebo, with an absolute risk reduction of 1.3%, and non-significant reductions in non-fatal heart attack and non-fatal stroke. "This approval marks an important milestone for millions of Americans living with type 2 diabetes, as cardiovascular disease is the number one cause of death in this patient population," said Mads Krogsgaard Thomsen, EVP and chief science officer of Novo Nordisk. "Victoza now offers people with type 2 diabetes and established cardiovascular disease an effective treatment option to both lower their blood glucose and reduce their cardiovascular risk."

11:19 EDT GameStop CEO sees 'tremendous demand' for future Switch products - Speaking on CNBC, GameStop (GME) CEO J. Paul Raines said that the strength of the Nintendo (NTDOY) Switch indicates that there's still a place for console gaming. Raines noted that the Switch has a 5-to-1 attach ratio and that there's "tremendous demand" for future Switch products. Raines added that he's "very bullish" on the company's prospects with the Switch and the iPhone 8 (AAPL).

11:04 EDT Duke proposes North Carolina rate change, seeks to cancel Lee Nuclear project - Duke Energy Carolinas, which serves central and western North Carolina, has announced its request to change customer rates. Duke Energy Progress, which serves electric customers in parts of central and eastern North Carolina and in the Asheville region, filed a similar request to adjust rates June 1 and Progress customers will not be affected by this new request, Duke stated. The filing with the North Carolina Utilities Commission requests to increase revenues by about $647M, for an overall average rate increase across all customer groups of 13.6%. Since Duke Energy Carolinas' last request to adjust rates in North Carolina in 2012, this represents approximately a 2.5% annual increase, the company said. As part of the rate request announcement, Duke stated: "Nuclear energy is also a vital component of Duke Energy's generation portfolio now and in the future - providing reliable, carbon-free electricity to the Carolinas. However, Duke Energy is seeking NCUC approval to cancel the development of the Lee Nuclear project due to the recent bankruptcy of Westinghouse Electric Company, a subsidiary of Toshiba Corporation, and other market activity. Most notably, risks and uncertainties to initiating construction on the Lee Nuclear project have become too great and cancellation of the project is the best option for customers. Duke Energy will maintain the license to build new nuclear at this site in the future if it is in the best interest of customers."

10:58 EDT Analysts defend supermarket chains after Amazon pledges Whole Foods price cuts - A number of Wall Street research firms are out defending stocks that fell yesterday after Amazon (AMZN) announced that it would cut prices at Whole Foods (WFM) stores as soon as its deal to buy the grocer closes this Monday. UBS wrote that the decline in the shares of Costco (COST) and Spouts Farmers (SFM) was "a bit" overdone, while SunTrust contended that Spouts and another supermarket chain, Kroger (KR), would probably not be hurt much by Amazon's move. UBS: Nearly 49% of Sprouts Farmers' stores are located within a ten minute drive of at least one Whole Foods store, noted UBS analyst Michael Lasser. Although Whole Foods' price cuts "could be a slight headwind" to Sprouts "over time," the company's unique produce pricing strategy and sourcing should help insulate it from the long term threat better than most, Lasser believes. About 33% of Costco's stores are within a ten minute drive of a Whole Foods, but over half of Costco's revenue is generated from "conventional groceries and gas," according to Lasser. As a result, the analyst believes that Costco's products are "complementary" with those of Amazon, giving Costco members "plenty of incentive" to renew their membership with the discount retail giant. SUNTRUST: Analyst David Magee says he doesn't expect Kroger (KR) and Sprouts to be significantly hurt by the move in the near-term. Calling Kroger's customer base distinct from that of Whole Foods, Magee says that only 10% of Kroger's stores are within three miles of a Whole Foods. That situation shouldn't change much, since both companies are growing their stores at "methodical" rates, he added. Furthermore, he says that 85%-90% of Kroger's products are "conventional," differentiating it from Whole Foods. Sprout's outlook is tied much more to "the broader pricing environment," while its current initiatives, including its private label offering and the expansion of its deli counters, are gaining traction, Magee stated. PRICE ACTION: After all three stocks were weak in afternoon trading yesterday on the heels of Amazon's announcement, this morning Sprouts has dropped another 2%, though Kroger has bounced back by 3% and Costco is fractionally higher.

10:50 EDT Ulta drops as sales growth slows amid Amazon, department store competition - Shares of Ulta Beauty (ULTA) plunged in early trading after reporting quarterly comparable sales that declined from last year. Ulta's report comes as department stores are discounting high-end cosmetics and as consumers shift to shopping online and away from physical stores. EARNINGS: After the market close on Thursday, Ulta reported second quarter earnings per share of $1.83 on revenue of $1.29B, beating analysts' estimates of $1.78 and $1.28B, respectively. Comparable sales were up 11.7%, driven by 5.5% transaction growth and 6.2% growth in average ticket, but that figure was below the 14.4% SSS growth Ulta experienced last year. Looking ahead, Ulta forecast third quarter EPS of $1.63-$1.68, at the low end of analysts' $1.68 consensus, on revenue of $1.331B-$1.353B, compared with estimates of $1.33B. Comp sales for Q3, including e-commerce, are expected to increase 9%-11%, below the year-ago increase of 16.7%. At the same time, Ulta raised its fiscal 2017 EPS growth view to the high 20% range from mid 20s and its FY17 SSS growth view to about 10%-11% from 9%-11%. Commenting on the quarter, Ulta said the company decided to prioritize earnings growth over comp sales growth, and, as a result, chose "not to run incremental promotions in July in order to comp over significant clearance activity" at the end of last year's Q2. Management noted that the company expects online sales to grow 50%-60% vs. its previous 50% view. Additionally, as other retailers are closing stores, Ulta is adding locations, saying that it will open about 100 new stores this year and remodel 11 locations. WHAT'S NOTABLE: Ulta's earnings report comes amid a more difficult retail environment. In July, Oppenheimer analyst Rupesh Parikh downgraded Ulta to Perform citing "softer" commentary from L'Oreal (LRLCY) on its earnings call regarding trends in its North American beauty business, increasing promotional activity from the department store channel and more difficult year-over-year comparisons that "could now signal a potentially more challenging beauty backdrop going forward." Additionally, online sites like Amazon (AMZN) are a threat. Amazon is said to be considering a partnership deal with Violet Grey, an "editorially driven online shopping destination" for luxury beauty products, according to a July report in WWD. Such a deal could potentially help Amazon land more prestige beauty brands, sources added to the publication at the time. Ulta also faces competition from department stores like Macy's (M), which are discounting high-end cosmetics and offering rewards. "The rapidly evolving retail environment is not new and we have never been complacent," Ulta CEO Mary Dillon said yesterday. ANALYST COMMENTARY: Analysts were mixed following Ulta's report, with Baird analyst Mark Altschwager cutting his price target to $295, citing lack of comp upside, expectations for higher margins, and competitive threats. BMO Capital's Shannon Coyne downgraded the stock to Outperform, citing the slowing beauty market, more promotional department stores and Amazon potentially gaining access to prestige brands. Meanwhile, Loop Capital analyst Anthony Chukumba said he has a difficult time finding anything in Ulta's report that makes him any less enthusiastic about the stock, but he also noted growing investor valuation concerns. Piper Jaffray analyst Erinn Murphy noted that Ulta Beauty's Q2 gross margin, which was an area of investor focus ahead of the company's report, outperformed expectations and she said Ulta "continues to play offense in the industry." Evercore ISI analyst Omar Saad said Ulta Beauty continues to be a favorite Long Position in the firm's Model Portfolio. PRICE ACTION: Ulta Beauty is down 10.5% to $209.16 in morning trading. Sally Beauty (SBH), another pure-play beauty products retailer, is down nearly 1%.

10:39 EDT MGT Capital Investments annouces further purchase of Bitcoin mining rigs - MGT Capital Investments announced that it has entered a purchase order with Bitmain Technologies for in excess of 1,000 S9 Antminer Mining rigs, with shipment expected in mid fourth quarter 2017. Following shipment and setup, MGT's Bitcoin mining operations are expected to generate $1.1M in monthly revenue, assuming current pricing and difficulty rates. Factoring in electricity, hosting and other direct operating costs, EBITDA from the company's Bitcoin mining operations is projected at $800,000 per month, prior to amortization of notes payable.

10:25 EDT Jefferies says buy Expedia, sell TripAdvisor amid transition - Research firm Jefferies upgraded online travel agency Expedia (EXPE) to Buy from Hold, predicting that the company's revenue will increase at least 10% annually for the next two years. However, the analyst downgraded TripAdvisor (TRIP) to Underperform, its equivalent of a sell rating, from Hold. The firm believes that the stock will only rise by a limited amount, while Expedia and Priceline (PCLN) present better opportunities for investors. EXPEDIA: Both Expedia and Priceline can do well in the online travel space, wrote Jefferies analyst Brent Thill. Expedia's revenue should grow by at least 10% in each of the next two years, and its margins should gradually improve "as it expands into new fragmented markets" and implements operational improvements, Thill wrote. Expedia's 2017 results should be boosted by improved business and consumer confidence, which should spur favorable travel trends, the analyst stated. Thill raised his price target on the stock to $180 from $140. TRIPADVISOR: The company continues to be focused on its transition to accepting bookings, but the turnaround won't be complete for a year, Thill stated. The "vast majority" of the benefits from the transition will only begin to materialize in 2018, he added. Additionally, Thill believes that the company is facing tough competition from Trivago (TRVG) and the online travel agencies. These competitors are spending a great deal on marketing, and TripAdvisor's own ad campaign will pressure its margins in the second half of this year and well into 2018, Thill warned. Also, the increased percentage of users who visit TripAdvisor's websites on mobile devices is pressuring the company's revenue, said Thill, who slashed his price target on the shares to $35 from $54. PRICE ACTION: In morning trading, Expedia lost 0.2% to $150, while TripAdvisor fell 3.7% to $41.72 per share.

09:50 EDT QAD Inc trading resumes

09:34 EDT Brightcove, Foxtel in live-streaming partnership for Mayweather-McGregor fight - Foxtel announced that it has partnered with Brightcove to livestream the Floyd Mayweather vs. Conor McGregor fight on August 27. The offering will complement Foxtel's existing Main Event service available over cable/satellite and in licensed venues. In addition to being able to watch the Pay-Per-View event at home, or at licensed venues, all Australian viewers can also subscribe to and stream the fight online, Foxtel noted.

09:18 EDT On The Fly: Pre-market Movers - UP AFTER EARNINGS: Splunk (SPLK), up 10%. ALSO HIGHER: Adamas Pharmaceuticals (ADMS), up 43% after the FDA approved Gocovri extended release capsules for treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy... Kamada (KMDA), up 11% after KEDRAB received U.S. FDA approval for passive, transient post-exposure prophylaxis of rabies infection... Pure Storage (PSTG), up 7% after reporting earnings and naming former Cisco (CSCO) executive Charles Giancarlo as its new CEO... Starbucks (SBUX), up 1% after Wedbush analyst Nick Setyan upgraded the stock to Outperform from Neutral. DOWN AFTER EARNINGS: GameStop (GME), down 9%... Veeva (VEEV), down 9%... Ulta Beauty (ULTA), down 7%. ALSO LOWER: Twitter (TWTR), down 1% after Jefferies analyst Brent Thill downgraded the stock to Hold from Buy, stating that he prefers Google (GOOGL), Facebook (FB) and Snap (SNAP) as plays on the digital video transition occurring across the social media space.

09:15 EDT PetMed: Sales of Tramadol, Gabapentin not driving company's growth

09:14 EDT PetMed: Company 'just as fundamentally strong today' as before AV report

09:04 EDT Capital Product announces new time charters for three MR product tankers - Capital Product Partners (CPLP) has secured new time charter employment for three MR tankers. The M/T 'Amadeus' secured employment with Repsol Trading S.A. (REPYY) for one year at a gross daily rate of $14,500. The charterer has the option to extend the time charter for an additional year at a gross daily rate of $14,750. The new charter will commence in October 2017. The M/T 'Aktoras' and the M/T 'Aiolos' have been chartered to Capital Maritime & Trading for ten to twelve months at $11,000 gross per day plus 50/50 profit share on actual earnings settled every six months. The vessels have been trading on voyage or short time charters following the expiry of their employment with BP Shipping Limited at the end of the first quarter of 2017. The new charters are expected to commence in September. The employment of M/T 'Aktoras' and M/T 'Aiolos' with Capital Maritime were unanimously approved by the Conflicts Committee of the Partnership. As a result of the above employments, the Partnership's charter coverage for 2017 and 2018 is 90% and 58%, respectively.

09:04 EDT Big Lots says consumer 'much more cautious' - Says discount space seeing better performance.

09:02 EDT Stellar Acquisition III confirms receipt of sponsor funds - Stellar Acquisition III announced that the company's sponsors have deposited into the company's trust account an aggregate of $402,536, representing $0.058 per public share. As a result, the period of time the company has to consummate a business combination has been extended by three months to November 24, 2017. The Sponsors will have the option, but no obligation, to extend such term two additional times, each by three months, up to May 24, 2018, by depositing an aggregate of $402,536 into the company's trust account, representing $0.058 per public share, in connection with each such extension.

09:01 EDT Northrim BanCorp raises quarterly dividend 5% to 22c per share - Northrim BanCorp announced that its Board of Directors increased the regular quarterly cash dividend by 1c, or 5%, to 22c per share. The dividend will be payable on September 15, 2017, to shareholders of record at the close of business on September 7, 2017.

08:30 EDT Dimension Therapeutics trading resumes

08:15 EDT Big Lots says expects Q3 gross margin 'similar' to prior year period - Says Q4 gross margin to be 'down slightly' compared to prior year period.

08:05 EDT Appliance Recycling expects continued profitability following cost reductions - Appliance Recycling announces that management anticipates increased profitability following recent corporate-wide efforts to reduce costs and streamline operations. The company recently launched an initiative to increase productivity and streamline operations, which management believes will result in increased profitability. As part of this initiative, management conducted an extensive audit of current costs to determine areas where cuts could be enacted, which led to an 18 percent reduction in overhead costs, which the company recently reported for the quarter ending July 1, 2017. In addition, several areas were identified where systems could be streamlined. The result was a significant cost savings that management believes will garner continued profitability going forward. This initiative is expected to continue in the coming quarters.

08:04 EDT Tesaro announces nine data presentations at ESMO meeting - TESARO announced that data from nine abstracts will be presented at the 2017 European Society for Medical Oncology annual meeting, September 8 to September 12, 2017, in Madrid. "We are excited that a wealth of data from the landmark ENGOT-OV16/NOVA trial will be presented at this year's ESMO Annual Meeting," said Mary Lynne Hedley, Ph.D., President and COO of TESARO. "Patient-reported quality of life data for patients treated with niraparib versus placebo will be featured in an oral presentation and the results of two post-hoc analyses, the observed exposure-response relationship of niraparib in gBRCAmut and non-gBRCAmut patients, and the safety and efficacy of niraparib in elderly patients, will be subjects for poster discussions. In addition, data from the Phase 1/2 trial of niraparib plus pembrolizumab in patients with triple-negative breast cancer or recurrent platinum-resistant ovarian cancer will be highlighted in a poster discussion. Finally, a poster will be presented detailing results from the Phase 1 study of TSR-042, our anti-PD-1 antibody."

08:03 EDT Regenxbio to acquire Dimension Therapeutics for $3.41 per share in stock - REGENXBIO (RGNX) and Dimension Therapeutics (DMTX) announced that they have entered into a definitive agreement under which REGENXBIO will acquire Dimension in an all-stock transaction for an implied value of approximately $3.41 per share. The boards of directors of both companies have unanimously approved the transaction. Upon completion of the acquisition, REGENXBIO will add two lead product candidates to its pipeline: DTX301 for the treatment of ornithine transcarbamylase deficiency, which is designed to use the NAV AAV8 vector to deliver a copy of the OTC gene to liver cells. DTX301 is being evaluated under an active investigational new drug application for a Phase I/II clinical trial; and DTX401 for the treatment of glycogen storage disease type Ia, which is designed to use the NAV AAV8 vector to deliver a copy of the glucose 6-phosphatase gene to liver cells. An IND application is anticipated to be filed for DTX401 in early 2018. Both DTX301 and DTX401 have been granted Orphan Drug Designation in the United States and Europe. In addition, REGENXBIO will acquire DTX201 for the treatment of hemophilia A. DTX201 is designed to use REGENXBIO's NAV Technology to deliver a copy of the Factor VIII gene to liver cells, and is partnered through a global development and commercialization collaboration with Bayer. An IND application is anticipated to be filed for DTX201 in early 2018. Under the terms of the definitive agreement, Dimension will, following consummation of the acquisition, become a wholly owned subsidiary of REGENXBIO. In addition, Dimension shareholders will receive 0.1573 shares of REGENXBIO in exchange for each of their shares in Dimension and are expected to own approximately 10.9% percent of the combined entity. It is anticipated that the transaction will close by year-end 2017, subject to approval by Dimension shareholders, receipt of any required customary regulatory approvals and the satisfaction of other customary closing conditions. Morgan Stanley is serving as financial advisor and Covington & Burling LLP is serving as legal counsel to REGENXBIO. MTS Health Partners, L.P. is serving as financial advisor and Goodwin Procter LLP is serving as legal counsel to Dimension.

08:01 EDT RADA Electronic receives $1M follow-on order for counter-UAV radar peripherals - RADA Electronic Industries announced that it has received a follow-on order worth approximately $1M for peripheral equipment to support the installation and operation of its Multi-Mission Hemispheric Radars. This order is in continuation to the strategic order for radars, worth over $8M, which was recently reported by the company. The radars and the peripherals will be used by a key US military force, providing it with air surveillance with emphasis on counter-UAV with the most advanced on-the-move capabilities. The systems are expected to be fielded for operational use soon after delivery.

07:32 EDT Amicus to highlight Fabry disease program at ICIEM - Amicus Therapeutics announced that 6 posters highlighting its Fabry program will be included in the 13th International Congress of Inborn Errors of Metabolism to be held September 5-8, 2017 in Rio de Janeiro, Brazil.

07:30 EDT XOMA trading resumes

07:03 EDT Shire announces collaboration with MicroHealth in hemophilia - Shire announced a collaboration with MicroHealth to support a free and secure care monitoring tool for hemophilia A and B patients with inhibitors and their care teams. Shire's collaboration with MicroHealth will help the start-up customize the tool with new features and information specifically for the 5-7 percent of hemophilia patients with inhibitors. Both companies remain independent in this collaboration and Shire does not have access to any patient, caregiver or other third-party data through this collaboration.

07:02 EDT Ritchie Bros. sells more than $49M of equipment in August Houston auction - Ritchie Bros. Auctioneers conducted its fourth Houston auction of the year this week, selling 3,700+ equipment items and trucks for $49M+ over two days, August 23-24, and setting a new site record for online sales. More than 4,500 people from 58 countries registered to bid in the auction, including 3,000+ people who registered to bid online. More than $30M, or 61% of the equipment, was sold to online bidders - a new record for the Houston site. U.S. buyers purchased 83% of the equipment, including 38% purchased by Texas buyers. International buyers from as far away Egypt, Japan, and the Netherlands purchased 17% of the equipment.

07:01 EDT Xoma announces license agreements for Gevokizumab, IL-1 beta IP portfolio - XOMA Corporation (XOMA) announced it has licensed the global commercial rights to gevokizumab, a novel anti-IL-1 beta allosteric monoclonal antibody, to Novartis (NVS). In a separate agreement, XOMA has granted Novartis a license to its intellectual property covering the use of IL-1 beta targeting antibodies in the treatment of cardiovascular disease.Under these agreements, XOMA will receive $31M in upfront payments, including a $5M equity investment, and is eligible to receive significant pre- and post-commercialization milestone payments plus tiered high-single to mid-double-digit royalties on net sales of gevokizumab. XOMA is also eligible to receive low-single-digit royalties on canakinumab sales in cardiovascular indications rising to mid-single-digit royalties under certain circumstances. Novartis has agreed to settle XOMA's EURO$12M debt to Les Laboratoires Servier and extend the maturity date on XOMA's debt to Novartis from September 2020 to September 2022.

06:56 EDT Kamada trading halted, news pending

06:11 EDT Ford CEO to provide strategic update on October 3 - On Tuesday, October 3, Jim Hackett, Ford president and CEO, will provide a strategic update to members of the investment community in New York. Also participating will be Bob Shanks, EVP and CFO, and other members of the Ford leadership team. Reference Link

06:06 EDT Big Lots reports inventory at Q2-end $810M vs. $809M a year ago - Inventory ended the second quarter of fiscal 2017 at $810M, compared to $809M for the second quarter of fiscal 2016. Inventory levels per store increased 1% compared to last year, partially offset by a lower store count year-over-year.

06:04 EDT Big Lots CEO says 'very pleased with our second quarter results' - David Campisi, CEO and President of Big Lots, stated, "I'm very pleased with our second quarter results. In a challenging retail environment with the pressures of online competitors and changing consumer shopping behaviors, our ownable and winnable merchandise categories are resonating with Jennifer and continue to demonstrate resiliency with solid sales growth in Q2. Our strategy is working as evidenced by our comps in ownable categories and our consistency of delivering growth in operating profit dollars and EPS. We are controlling what we can control and our teams are energized and excited as our new Fall merchandise has begun to arrive in stores."

04:53 EDT Guatemalan Court provisionally suspends mining license of Minera San Rafael - Tahoe Resources reported that it has learned through unconfirmed sources that the Guatemalan Constitutional Court issued a decision upholding the lower court's preliminary decision to provisionally suspend the mining license of Tahoe's Guatemalan subsidiary, Minera San Rafael. This decision responds to an appeal filed by Minera San Rafael in an action brought by the anti-mining organization, CALAS, against Guatemala's Ministry of Energy and Mines in May. CALAS alleged that MEM violated the Xinca Indigenous people's right to consultation in advance of granting the Escobal mining license to MSR. The Constitutional Court decision upholds the lower court's preliminary decision to temporarily suspend the license to operate the Escobal mine until the definitive constitutional claim is heard on the merits, which hearing is scheduled for August 28th. The Court is expected to issue a ruling within the next several months following the August 28th hearing. The Company understands that MEM complied with ILO Convention 169 before it issued the Escobal license. Top government officials have expressed dismay at the significant economic, human and environmental impacts resulting from the decision to suspend the Escobal license. The leading private sector industrial chamber has taken independent legal action to challenge the suspension that has damaged many thousands of workers and their families. The municipal road to the Escobal mine continues to be blocked by protestors. The Company continues to work diligently with the government, community leaders and others to resolve the situation peacefully and expeditiously, however, the road blockage shows no signs of immediate resolution. As a result of the suspended operations at Escobal, the Company will continue to reevaluate its previous multi-year guidance. The financial impacts to the Company are currently under review to assess effects of the suspended operations to longer term capital and exploration programs. Until operations are resumed, the Company will not be able to access the full capacity of the revolving credit facility entered on July 18, 2017, and may continue to be subject to events of default. The Company's balance sheet remains strong, with a quarter-end cash balance of over $190M, and the Company continues to look forward to pursuing its growth goals in the gold businesses once operations recommence.

04:46 EDT Valmont announces sale of mining consumables business to Moly-Cop - Valmont Industries announced a definitive agreement to sell its Australian mining consumables business to Moly-Cop, a portfolio company of American Industrial Partners, a private equity firm headquartered in the United States. This business, known as Donhad Pty. Ltd., was acquired as part of Valmont's acquisition of Delta plc in May 2010 and is reported as part of the Company's Energy and Mining segment, generating $83.1M in revenues in 2016. The Company plans to use the proceeds from the sale to reinvest in opportunities to grow and improve its existing infrastructure and agricultural businesses. The closing of the transaction is subject to customary conditions and is expected to be completed by the end of 2017, the timing of which is also dependent upon receiving Australian regulatory approvals. No further transaction details were disclosed.